Evolus, Inc.
- Jurisdiction
United States - LEI
549300VYQRYBQOT8V419 - ISIN
US30052C1071 (EOLS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. Read full profile
Stock price
Fundamentals
- Net revenue
€238.09M - Gross margin
66.7% - EBIT
-€37.04M - EBIT margin
-15.6% - Net income
-€53.19M - Net margin
-22.3%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
No dividend payouts
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Yamagishi-Dressler Tomoko | Chief Marketing Officer |
|
|
|
|
| Stewart Brady | N/A |
|
|
|
|
Earnings Calls
Latest earnings call: May 7, 2024
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| George Soros |
|
|
|
Sell |
| Peter Brown |
|
|
|
Buy |